<DOC>
	<DOCNO>NCT02570711</DOCNO>
	<brief_summary>To evaluate Safety efficacy ACP-196 nab paclitaxel/gemcitabine subject metastatic pancreatic cancer use standard response criterion</brief_summary>
	<brief_title>Study Nab Paclitaxel/Gemcitabine Alone Combination With ACP-196 Subjects With Previously Untreated Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Men woman ≥ 18 year age . ECOG performance status 0 1 . Histologically cytologically confirm metastatic adenocarcinoma pancreas . No previous radiotherapy , chemotherapy investigational therapy treatment metastatic disease . Prior treatment 5FU gemcitabine administer radiation sensitizer adjuvant setting allow , provide least 6 month elapse since completion last dose linger toxicity present . Prior malignancy ( pancreatic cancer ) , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year . Known central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , symptomatic inflammatory bowel disease , partial complete bowel obstruction , gastric restriction bariatric surgery , gastric bypass . Biliary obstruction presence percutaneous biliary drain . Note : Subjects endobiliary stent may participate long enrollment criterion relate serum bilirubin concentration meet . Breastfeeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>